AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £381.32m
- £404.16m
- £55.20m
RCS - Allergy Therapeutics - EAACI Early Career Research Award
AnnouncementREG - Allergy Therapeutics - Interim Results for six months ended 31 Dec 2024
AnnouncementREG - Allergy Therapeutics - Advancement to final phase of PROTECT trial
AnnouncementREG - Allergy Therapeutics - New Executive Long Term Incentive Awards
AnnouncementRCS - Allergy Therapeutics - Presentations at 2025 AAAAI / WAO Joint Congress
AnnouncementREG - Allergy Therapeutics - Grass MATA MPL Phase III data published in Allergy
AnnouncementREG - Allergy Therapeutics - Grant of Options
AnnouncementREG - Allergy Therapeutics - Half Year Trading update
AnnouncementREG - Allergy Therapeutics - PDMR Dealing and Total Voting Rights
AnnouncementREG - Allergy Therapeutics - Director/PDMR Shareholding
AnnouncementREG - AIM - AIM Notice - 27/12/2024
AnnouncementREG - Allergy Therapeutics - Exercise of Options and Total Voting Rights
AnnouncementREG - Allergy Therapeutics - Block Listing Interim Review
AnnouncementREG - Allergy Therapeutics - Result of Annual General Meeting
AnnouncementREG - Allergy Therapeutics - Positive Interim Data from PROTECT Trial
AnnouncementREG - Allergy Therapeutics - First Patient Dosed in G308 Paediatric Trial
AnnouncementREG - Allergy Therapeutics - Submission of MAA for Grass MATA MPL
AnnouncementREG - Allergy Therapeutics - Notice of 2024 Annual General Meeting
AnnouncementREG - Allergy Therapeutics - Audited Preliminary Results 2024
Announcement